In Collaboration with the University of Manitoba the Health Sciences Centre Winnipeg presents A Shared Health facility THE 24th ANNUAL BUG DAY Abstracts Tuesday, October 20, 2020 Join us digitally by registering before October 19th at: www.hsc.mb.ca/Bugday.html Bug Day Agenda 0750 - 0800 Opening Remarks 1200 - 1215 Questions and Answers Perry Gray, MD, Shared Health, Manitoba 1215 - 1245 Lunch Break 0800 - 0900 Medical Grand Rounds 1245 - 1300 Restarting Professional Sports in a Pandemic: The COVID-19 Pandemic: Lessons Learnt from the National Hockey League Looking Back to Move Forward Peter MacDonald, MD, University of Manitoba Guillaume Poliquin, MD, Public Health Agency of Canada Brent Roussin, MD, Manitoba Health 1300 - 1315 COVID-19: Children Aren’t Little Adults Paul Van Caeseele, MD, Manitoba Health Joanne Embree, MD, University of Manitoba John Embil, MD, Winnipeg Regional Health Authority 1315 - 1330 Ready, Set, Go! 0900 - 0915 Positive or Not? Laboratory Testing for COVID-19 Operational Readiness in a Time of Uncertainty Jared Bullard, MD, University of Manitoba Taslim Savji, MSc / Jason Goto, MSc, AnalysisWorks 0915 - 0930 Predicating What Comes Next: Modelling a Pandemic 1330 - 1345 Questions and Answers Nicholas Ogden, DPhil, Public Health Agency of Canada 1345 - 1400 The COVID-19 Pandemic: What Were the 0930 - 0945 COVID-19 Immunity, and a Vaccine: Missed Steps? Fact or Wishful Thinking Duane Funk, MD, University of Manitoba Yoav Keynan, MD, University of Manitoba 1400 - 1415 COVID-19 and the Economy: What Lies Ahead? 0945 - 1000 Questions and Answers Michael Benarroch, PhD, University of Manitoba 1000 - 1015 Break 1415 - 1430 Viruses are Everywhere! Cyber Security Risk 1015 - 1030 Staying on Track: Management Tips from the Investment Industry Incident Command at the Time of Health Care Crisis Sean Shore, LLM, Canadian Compliance & Ronan Segrave, MSc, Shared Health, Manitoba Regulatory Law 1030 - 1045 Therapies of COVID-19: Fact or Fantasy 1430 - 1445 Questions and Answers Ryan Zarychanski, MD, University of Manitoba 1445 - 1500 Break 1045 - 1100 Blowing in the Wind: 1500 - 1515 Coping with the COVID-19 Pandemic using Virtual Protective Environments in the Health Care Setting Mental Health and Substance Use Care Tools Craig Doerksen, P.Eng, Shared Health, Manitoba Jitender Sareen, MD, University of Manitoba 1100 - 1115 Questions and Answers 1515 - 1530 Keep your Distance! How to Manage 1115 - 1130 Flattening the Curve: Relationships in the COVID-19 Pandemic Public Health Ethics Applied to Pandemics Myrna Friedenberg, MSW, Family Therapist, Sandor Demeter, MD, University of Manitoba Private Practice 1130 - 1145 What to do with the Last Ventilator? 1530 - 1545 COVID-19 from a Law Enforcement Prespective Adrian Robertson, MD, University of Manitoba Shane Wepruk, Detective Sergeant 1145 - 1200 Personal Protective Equipment for Vivian Smith, Detective Winnipeg Police Service Respiratory Pathogens Mark Loeb, MD, McMaster University 1545 - 1600 Questions and Answers For more information, call (204) 787-4654 or visit Visit site to download Donations abstract booklet, brochure, gratefully www.hsc.mb.ca/Bugday.html and other important material accepted This program has received in-kind support from the University of Manitoba The COVID-19 Pandemic: Looking Back to Move Forward Brent Roussin, MD1, Guillaume Poliquin, MD,2, Paul Van Caeseele, MD3, John Embil, MD4 1Manitoba Health, 2National Microbiology Laboratory, 3Cadham Provincial Laboratory, 4Winnipeg Regional Health Authority Abstract: With the reports of a cluster of severe pneumonia cases in Wuhan, China in late 2019 followed by the identification of a novel coronavirus weeks later, Public Health began preparation for a pandemic response. Manitoba Health, Seniors and Active Living, and Shared Health initiated the co-chaired Incident Management Structure on February 3, 2020. This was province wide planning for both the public health and health care systems. One of the greatest challenges early in the pandemic was obtaining sufficient and credible information, as accurate descriptive epidemiology is vital in responding to a novel pathogen. Decisions had to be made rapidly, often without complete information. The foundation of any response to a communicable pathogen is rapid case identification and isolation followed by expeditious and thorough contact investigation, isolation and follow up. All of this required increased capacity in testing, contact tracers and isolation centres. Without any known treatments or vaccine, Public Health had to rely on non-pharmaceutical interventions. This was achieved through messaging and through the use of the Public Health Act. These coercive measures likely provided benefit but also had impacts on other aspects of health. The Canadian success with managing the COVID-19 pandemic to date has relied upon excellent interaction between federal, provincial and territorial governments. One of the major challenges has been discussions surrounding borders and travel within Canada and between Canada and other countries. As we prepare for autumn 2020 and winter 2021, we will be faced with the additional challenge of the respiratory virus season. Objectives By attending this session, the attendee will be able to: 1. State what the positive predictive value of a test means 2. State the meaning of the basic reproductive number 3. List the factors involved in containing a pandemic Self-assessment Questions: (Select the best answer) 1. Which of the following is the best description of the basic reproductive number? a. The number of contacts of a specific case that develops illness. b. The average number of infections produced by an infected individual in a completely susceptible population. c. The number of live births reported in a geographic area during a specific time interval. 2. Regarding the positive predictive value (PPV) of a test, which of the following is true? a. PPV decreases as disease prevalence decreases. b. PPV increases as disease prevalence decreases. c. PPV is an inherent value of a given test and does not change related to disease prevalence. 3. Which of the following best describes the incubation period of a communicable pathogen? a. The period of time that a communicable agent can be transmitted from one individual to another. b. The period of time between exposure to a pathogen and the onset of communicability. c. The period of time between exposure to a pathogen and the onset of the first sign or symptom. Positive of Not? Laboratory Testing for COVID-19 Jared Bullard, MD Cadham Provincial Laboratory, and Section of Pediatric Infectious Diseases Departments of Pediatrics and Child Health, University of Manitoba Abstract: Testing often helps inform clinical decisions and public health policy. This has certainly been the case with SARS-CoV-2/COVID-19. It is essential to understand the limitations of different kinds of tests, particularly as they relate to whether cases would be considered infectious or not. The main method of diagnosing COVID-19 is RT-PCR. Laboratory developed testing (LDT) and commercial products have risen to the challenge of developing effective tests that can screen large numbers of patients. In addition, point of care tests (POCTs) are a useful adjunct to traditional laboratory testing. Serology for COVID-19 has more limited applications compared to RT-PCR but will be important in fully defining the disease spectrum of COVID-19 and its impact on the population. Objectives: By attending this session the attendee will be able to: 1. State the most appropriate specimens for diagnosing COVID-19. 2. Recognize the various SARS-CoV-2 RT-PCR tests available and the advantages and challenges of each. 3. List the indications for SARS-CoV-2/COVID-19 serology. Self-assessment Questions: (Select best answer) 1. What is NOT an appropriate clinical specimen for diagnosing COVID-19? a. Feces b. Blood/serum c. Nasopharygneal swab d. Broncheoalveolar lavage 2. All are advantages of SARS-CoV-2 RT-PCR POCT EXCEPT: a. Results are available faster b. Can be used in the community c. Easier for non-laboratory healthcare professionals to use d. More affordable than traditional lab testing 3. Which of the following patients is least likely to be infectious? a. A 7 year old boy with mild symptoms compatible with COVID-19 for 3 days b. A 68 year old woman with co-morbidities admitted to the ICU after progressive respiratory failure on day 6 of illness c. A 26 year old man diagnosed with COVID-19 by NP swab 2 weeks ago d. A 43 year old woman with fever, cough and mild SOB for 2 days who’s partner was diagnosed with COVID-19 Predicting What Comes Next: Modelling a Pandemic Nicholas Ogden, DPhil National Microbiology Laboratory, Public Health Agency of Canada Abstract Severe acute respiratory syndrome virus 2 (SARS-CoV-2), likely a bat-origin coronavirus, spilled over from wildlife to humans in China in late 2019 manifesting as a respiratory disease, coronavirus disease 2019 (COVID-19), which spread initially within China then globally, resulting in a pandemic. This presentation will describe predictive modelling of COVID-19 within the Public Health Agency of Canada to model the effects of non-pharmaceutical interventions (NPIs) on transmission of SARS- CoV-2 in the Canadian population to support public health decisions. Two modelling approaches, an agent-based model and deterministic compartmental models, will be described. These modelling studies underline key features of the epidemiology of COVID-19, potential impacts on Canadians, and the NPIs that need to be in place to lifted restrictive closures yet preventing resurgence of the epidemic. Objectives: By attending this session, the attendee will be able to: 1. Define the epidemiology of COVID-19 2. Outline the challenges in controlling COVID-19 3. State how public health measures may control the epidemic Self-assessment Questions: (Select the best answer) 1. Why does COVID-19 present a huge challenge to health of Canadians and public health? a. There is no existing immunity in the Canadian population b. COVID-19 has a potentially very high reproduction rate c.